Recombinant virus-like particles encoded by multi-gene vector

ABSTRACT

The invention describes novel virus-like particles for use as vaccines, diagnostic tools and R&amp;D tools based on recombinant DNA and cell cultivation techniques for production. The recombinant virus-like particles of the invention are assembled by polypeptide chains that incorporate several, in particular two or more, different epitopes which are selected either (a) from different viral strains of the same virus and/or (b) from different serotypes of the same virus and/or (c) from different viral strains specific for different hosts. These epitopes are then displayed on the particle surface.

FIELD OF THE INVENTION

The invention relates to recombinant virus-like particles comprisingepitopes from different virus strains, and vectors encoding these.

BACKGROUND OF THE INVENTION

There is an increasing interest in small natural biomolecules using themin different aspects in biomedicine, nanotechnology and materialscience. Virus simulators, virus capsids or virus-like particles arevery attractive because of their regular structure, their homogenousparticle size, their stability, the ease of production and the potentialfor manipulation. Virus-like particle possess dynamic structures, theirinterior is accessible and furthermore the coat is modifiable. Dependenton the application the virus-like particles could have an envelope ornot and could be chosen as virus simulators. These embodiments could beused as new biological entities or targets, as vaccines, as antigens forantibody production, as research tools, as diagnostic tool, for drugdelivery and bioconjunctions. These virus simulators are formed byself-assembly of envelope and or capsid proteins of many viruses. Thesize varies between 22-150 nm dependent on the morphology of theparticular virus. The virus simulators are non-infectious because theyassemble without incorporating genetic material. Dependent on theapplication foreign genetic material could be included in the hereindescribed virus simulator.

A promising application of these virus simulators is the production ofvaccines against various diseases because their repetitive, high densitydisplay of epitopes elicit often a strong immune response. The smallsize of particles is an advantage for uptake by dendritic cells.Chimeric virus simulators offer an enormous potential in selective,multi-epitope, multi-protein, multi-serotype, multi-strain, ormulti-species presentation.

There exist many expression systems for the production of virussimulators which include the baculovirus/insect cell system, variousmammalian cell lines, either stably or transiently transfected ortransduced with viral expression vectors, furthermore various species ofyeast including Saccharomyces cerevisiae and Pichia pastoris, andEscherichia coli and other bacteria.

Vaccination is dependent on the generation of a sufficient immunity toprotect from infectious diseases. The mostly used attenuated virusvaccines rely on limited replication of the virus in the host followingimmunization. But this kind of vaccination may cause severe reactions insome patients. Therefore the development of virus-like particles (VLP)as subunit vaccines is an advantage because the particles lack ingeneral DNA or RNA genome but have the authentic conformation of thenatural virus.

Vaccination is one of the most potent and cost-effectivecounter-measures to the threat of e.g. seasonal or pandemic influenzaoutbreaks. The ease of spread as an aerosol and the cause for a severeillness especially to susceptible humans are the major reasons whyinfluenza is one of the most devastating viral diseases. Currentlylicensed seasonal vaccines are only partially protective, and theegg-based production is very time-consuming and cost-intensive. Thisstrategy is vulnerable to the unanticipated emergence of epidemicstrains that are poorly matched or not matched at all by the vaccine.Due to the danger of emerging strains of avian influenza or influenza ofother origin novel vaccine approaches are necessary.

In another aspect the research in the field of several important viruseslike HCV, HIV, Ebola etc. is very difficult because of biosafety issues.Until now there exist only a few models for investigation of viral entryand viral trafficking. Diagnostic tools are based on the genome of theseviruses because of the lack of appropriate non-infectious virus models.

Presently commercial human influenza vaccines contain hemagglutinin astheir only or main viral antigen. Their production starts from virusesgrown on embryonated chicken eggs or, more recently, in mammalian cellsin tissue culture. The production in eggs requires selection of highyield, reassorted virus strains, is limited in capacity, time-consuming(6-8 months), and expensive. Beyond that it can cause problems invaccinated persons allergic to egg protein. The production is onlypossible with non-lethal bird strains. One of the most importantdisadvantages of the egg-based production is the limited capacity. Incase of a pandemic the production of the seasonal influenza vaccine hasto be stopped in favour of a pandemic influenza vaccine production whichcould result in even more lethal events in the long run.

Vaccines against viral diseases rely traditionally on attenuated virusstrains or inactivation of infectious virus. An appropriate environmentis necessary for highly pathogenic or haemorraghic viruses whichconstrains the production possibilities because of the biosafety level(e.g. BL3/BL4). For some viruses like human papilloma virus theattenuation will not be sufficient because the virus cannot bepropagated in vitro. The ability to generate human papilloma virus(HPV)-like particles based vaccines (Gardasil, Cervarix) has changed theprospects for preventing cervical cancer in woman.

Due to the danger of emerging strains of avian influenza or otherorigin, novel vaccine approaches are necessary which result in anenhanced protection.

SUMMARY OF THE INVENTION

The invention relates to a recombinant virus-like particle comprisingtwo or more different epitopes or different proteins comprising epitopeswhich are selected either (a) from different viral strains of the samevirus and/or (b) from different serotypes of the same virus and/or (c)from different viral strains specific for different hosts. Theserecombinant virus-like particles are useful as vaccines, and theinvention also relates to these vaccines.

Furthermore the invention relates to a vector comprising two or morepolynucleotides coding for different epitopes or for different proteinscomprising epitopes which are selected either (a) from different viralstrains of the same virus and/or (b) from different serotypes of thesame virus and/or (c) from different viral strains specific fordifferent hosts, and to host cells comprising these vectors.

BRIEF DESCRIPTION OF THE FIGURE

FIG. 1: Schematic representations of vector constructs expressingmultiple-epitope virus-like particles.

(A) (SEQ ID NO:1) Multivalent influenza A virus simulator containingdifferent epitopes (M1, M2) from H1N1 viral strains as well as H3N2 (HA,NA) viral strains

(B) (SEQ ID NO:2) Chimeric human papilloma virus-like particlecontaining an epitope (L1) from serotypes HPV16 and HPV18

(C) (SEQ ID NO:3) Expression vector construct with embedded epitopes(HA, NA, M1, M2) from influenza B/Florida isolates

(D) (SEQ ID NO:4) Vector construct for expression of an epitope (L1) ofHPV16 and HPV18 serotypes where both genes are under the control ofdifferent promoters

(E) (SEQ ID NO:5) Same Vector construct as (B) with deletion of promoterp10

The vectors contain two promoters P1 and P2 (

,

) selected from polh, p10 and p_(XIV) very late baculoviral promoters,vp39 baculoviral late promoter, vp39polh baculoviral late/very latehybrid promoter, pca/polh, pcna, etl, p35, egt, da26 baculoviral earlypromoters; CMV, SV40, UBc. EF-1, RSVLTR, MT, P_(DS47), Ac5, P_(GAL) andP_(ADH) The terminator sequences T1 and T2 (T) are selected from SV40,HSVtk or BGH (bovine growth hormone). Furthermore the vector containsthe transposon sites TnL and TnR (L,R) for generation of MultiBacbacmid,a loxP site (LP) for site specific homologous recombination (plasmidfusion), an origin of replication (O), ampicillin (A) and gentamycine(G) resistance genes and defined restriction sites.

FIG. 2: Analysis of expressed chimeric influenza virus-like particles.

(A) The conformation of secreted (A, lane 2) as well as intracellularVLPs (prepared from SEQ ID NO:1, A, lane 1) is verified byimmunoblotting using specific antibodies against the proteins HA (H3),NA (H3) and M2 (H1). Lane 3=ladder, protein sizes in kDa. The epitopesare co-localized, which means that they are assembled in one particle.

(B) Visualization of the chimeric Influenza virus-like particle(prepared from SEQ ID NO:3) by electron microscopy using negativestaining with uranyl acetate. The spikes representing epitope HA arevisible. The size of the particle is in the range of 50-80 nm.

FIG. 3: Chromatographic purification and analysis of secretedmulti-epitope influenza virus-like particles prepared from SEQ ID NO:1.

(A) Chromatogram of gel filtration purification. The first peak (1)contains the virus-like particle (VLP). The other peaks (2-6) representcontaminant proteins.

(B) Coomassie-stained SDS-PAGE. The multiple epitopes of the virus-likeparticles are verified by analyzing different fractions from the 1^(st)peak (1) representing the start (lane 1), middle (lane 2) and end (lane3) part of the VLP containing peak. The ladder [kDa] is represented leftof the first lane. Detection of epitopes is indicated by arrows.

(C) Western blot analysis according to Coomassie-stained gel using ananti-HA antibody.

FIG. 4: Functionality of nature-like influenza virus-like particles(VLP).

Twofold serial dilution series (1:2 to 1:2048) of the purified VLPs(prepared from SEQ ID NO:3) are analyzed by standard hemagglutinationassay. 50 μL purified particle solution was coated onto 96-well plateincubated with red blood cells (erythrocytes). The influenza VLP (1,upper part) are able to agglutinate red blood cells in a dose dependentmanner. Highest dilution is 1:1024. In contrast PBS, used as control(C), leads only to precipitation of erythrocytes, visible as a “dot” inthe middle of the well.

FIG. 5: In vivo evaluation of multi-epitope influenza virus-likeparticles.

Mice are immunized either with 50 ng (mice 1-5) or 100 ng (mice 6-10)purified VLP prepared from SEQ ID NO:3, and as control with PBS (mice11-12). Antibody titers after prime injection (3 weeks post injection)are indicated as white boxes, titers after a boost injection areindicated as black boxes (6 weeks post injection). The titers arepresented as dilution of mice sera (y-axis). VLPs effectively stimulatean antibody immune response. The best results are obtained whenimmunization is performed with 100 μl (mice 6-10), indicating a dosedependent immune response. A clear increase of the amount of anti-VLPantibodies is observed after boost. As expected, control animals (mice11-12) showed no immune response.

FIG. 6: Confirmation of specific immune response to multi-epitopeinfluenza VLP by hemagglutination inhibition assay.

The ELISA test was performed with sera taken at week 6 post injection toanalyze the presence of specific anti-HA antibodies. Multi-epitopevirus-like particles prepared from SEQ ID NO:3 were coated onto a96-well plate, mixed with the sera and incubated for 30 min. The serawere tested in a series of twofold dilutions (1:2 to 1:1024). Afterincubation erythrocytes were added and incubated for further 30 min.Specific anti-Influenza-HA antibodies from different mice binding tomulti-epitope virus-like particles result in inhibition of erythrocyteagglutination up to a dilution 1:128 (1) and dilution 1:256 (2), visibleas erythrocyte precipitation (“dot”) in the middle of the well. Nohemagglutination inhibition is observed with sera sample of the controlmouse (C).

FIG. 7: Screening of best expression conditions using 50 mL bioreactors.

The initial cell amount in the range of 1-2×10⁶ cells/mL (TOI, 1 or 2),virus inoculum (MOI, 0.01-2) and time of harvest (days post infection,d2-d6) were determined by dot blot analysis.

(A) Determination of best expression parameters of an expressionconstruct carrying only one epitope L1 which is used as control.Detection by a specific anti-HPV18 antibody (Abcam).

(B) Determination of best expression parameters of a multi-epitopeexpression construct carrying two epitopes from different serotypes (SEQID NO:2). Detection by specific anti-HPV16- (Camvir, Santa Cruz) andanti-HPV18- (Abcam) antibodies against the two epitopes HPV16 L1 andHPV18 L1.

FIG. 8: Chromatographic purification and analysis of multi-epitope humanpapilloma virus-like particles prepared from SEQ ID NO:2.

(A) Chromatogram of anion exchange chromatography using DEAE-sepharosecolumn. Flow through (1), wash (2) and elution peaks (3-5) are indicatedby numbers (1-5). The increased ionic strength of elution buffer isshown by a line [%]. 3=elution with 300 mM NaCl, 4=elution with 420 mMNaCl, 5=elution with 680 mM NaCl.

(B) Coomassie-stained SDS-PAGE. The presence of multiple epitopes of thevirus-like particles were verified by analyzing different parts of thechromatogramm. Lane1=ladder [kDa], lane 2=VLP before purification, lane3=wash step, lane 4=elution with 300 mM NaCl, lane 5=elution with 420 mMNaCl, lane 6=elution with 500 mM NaCl, lane 7=elution with 680 mM NaCl.Epitopes are indicated by arrows (L1).

(C) Western blot analysis with coomassie-stained gel using specificantibodies against two epitopes which are indicated by arrows (L1).

DETAILED DESCRIPTION OF THE INVENTION

The invention aims at producing novel virus-like particles for use asvaccines, diagnostic tools and R&D tools based on recombinant DNA andcell cultivation techniques for production. Particles of the inventionmeet the demand for vaccines suitable to combat a potential pandemicinfluenza outbreak. The recombinant virus-like particles of theinvention are assembled by polypeptide chains that incorporate several,in particular two or more, such as two, three, four or five, or alsomultiples of three, such as six, nine or twelve, different epitopes ordifferent proteins comprising epitopes which are selected either (a)from different viral strains of the same virus and/or (b) from differentserotypes of the same virus and/or (c) from different viral strainsspecific for different hosts. These epitopes are then displayed on theparticle surface. Selection of epitopes from different strains,serotypes and/or viruses specific for different hosts results in amultifunctional virus-like particle mimicking natural changes of virusesas they occur in nature, e.g. as observed in April 2009 during theoutbreak of swine influenza. State of the art virus-like particles areeither composed of a single protein or comprise up to three differentepitopes derived from the same viral strain. The particle of theinvention is encoded by a single DNA vector, either viral or plasmidbased, which is used for the production in a host cell such as insectcells, bacterial cells and mammalian cells. In a preferred embodiment,the DNA vector is a baculovirus vector and the host cell an insect cell.

Epitopes of the invention are immunogenic peptides consisting of between4 and 1000 amino acids, preferably between 6 and 100 amino acids, andare preferably neutralization epitopes. Neutralization epitopes areepitopes which, when bound by antibodies as the results of animmunogenic response, lead to neutralization of the virus carrying sucha neutralizing epitope. Epitopes as understood herein may be repetitive,and may be part of a larger protein, in particular part of an antigen,part of a viral surface protein or part of a viral membrane protein.Such epitopes incorporated in viral surface proteins or viral membraneproteins are preferred. If the intended use of the virus-like particlesaccording to the invention is as a R&D tool, diagnostics tool or a virussimulator it is important that the epitopes are part of complete viralproteins providing a complete virus-type surface.

Different viral strains of the invention are, for example, differentstrains of influenza virus, for example influenza virus A strains H1N1,H5N1, H9N1, H1N2, H2N2, H3N2 or H9N2, or also influenza virus B orinfluenza virus C.

Different serotypes of the invention are, for example, differentserotypes of human papilloma virus (HPV), for example serotypes 6, 11,16, 18, 31, 33, 35, 39, 45, 48, 52, 58 62, 66, 68, 70, 73 and 82, butalso from the proto-oncogenic types HPV 5, 8, 14, 17, 20 and 47 or frompapilloma relevant types HPV 6, 11, 13, 26, 28, 32 and 60.

Virus strains specific for different hosts means particularly adapted tothe corresponding host, and are, for example, human influenza virusstrains, swine influenza virus strains and avian influenza virusstrains. In this context, specific for a host means that the virus iseasily transmitted from one host to another host of the same type, butnot to a different type of host. For example, an avian virus strain iseasily transmitted from birds to other birds, but not to other animalsor to humans.

In a preferred embodiment the particle comprising epitopes fromdifferent strains, serotypes and/or viruses specific for different hostsare combined with B- and/or T-cell epitopes in order to induce a broaderimmune response.

In another preferred embodiment the virus-like particle consists ofproteins forming a complete virus-like surface, optionally furthercomprising capsid and nucleopore proteins.

The virus-like particle of the invention may further comprisefluorescent proteins, proteins useful for purification purposes of theparticles or for attaching a label, and proteinaceous structuresrequired for transport processes and stability.

The herein described polypeptides and virus like particles are generatedin a shorter time and in unlimited amounts compared to actual vaccinemanufacturing processes, due to the use of specific genetic and processengineering tools. The capability to assemble the required viral genesby modern molecular biology methods, such as the MultiBac technology (WO2005/085456; I. Berger et al., Nature Biotechnology 22, 1583, 2004),Polybac technology (WO 2007/054250), or gene synthesis, for instance,allows for fast assembly of the coding DNA vector. The use of thesetechnologies does not require any physical transfer of original,potentially dangerous viruses during the development, manufacturing oradministration of virus-like particles and vaccines of the invention.For the construction of particles of the invention it is sufficient touse nucleotide sequences from an infected individual. This stands inmajor contrast to classical egg-based methods for generating vaccines,which require genetically modified virus as a seed-strain virus.Particles of the invention are manufactured using modern disposabletissue culture techniques which allow for high production capacity. Inthe preferred embodiment of baculoviral vector and insect cells as hostcells the manufacturing process can be quickly set-up, and productiontimes are short, i.e. in the range of weeks rather than months comparedto egg-based methods. Additionally, the construction of disposabletissue culture facilities is less time-consuming and costly compared tosetting up an egg-based facility. As a consequence large amounts ofvaccine for a full population can be produced and re-produced withinshort time frames, and several different types of vaccines, e.g.seasonal influenza vaccines and pandemic influenza vaccines, can easilybe produced in parallel. Difficult decisions by health authorities forthe one or the other vaccine due to capacity limits of egg-based vaccinemanufacturing plants will not be required.

The invention relates to a recombinant virus-like particle comprisingtwo or more, such as two, three, four or five, or also multiples ofthree, such as six, nine or twelve, different epitopes or differentproteins comprising epitopes which are selected either (a) fromdifferent viral strains of the same virus and/or (b) from differentserotypes of the same virus and/or (c) from different viral strainsspecific for different hosts. Preferred are recombinant virus-likeparticle comprising three or more, preferably four or more differentepitopes or different proteins comprising epitopes. Likewise preferredare recombinant virus-like particle comprising multiples of three, suchas six, nine or twelve different epitopes or different proteinscomprising epitopes. The epitopes are selected from two differentstrains, serotypes or virus strains specific for different hosts, orfrom three different strains, serotypes or virus strains specific fordifferent hosts, or from four different strains or serotypes. Preferredare virus-like particles comprising several epitopes from threedifferent strains or serotypes. Likewise preferred are virus-likeparticles comprising several epitopes from virus strains specific fortwo or three different hosts.

Furthermore the invention relates to a vector comprising two or more,such as two, three, four or five, or also multiples of three, such assix, nine or twelve, different polynucleotides coding for epitopes orfor different proteins comprising epitopes which are selected either (a)from different viral strains of the same virus and/or (b) from differentserotypes of the same virus and/or (c) from different viral strainsspecific for different hosts. “Polynucleotides” as used herein mayrepresent a chain of between 12 and 3′000 nucleotides, includesoligonucleotides as commonly designated, and may be a viral gene or openreading frame from the mentioned different viral sources, in particulargenes or open reading frames encoding viral surface proteins or viralmembrane proteins.

Preferred are vectors coding for preferred virus-like particlesmentioned hereinbefore.

Most preferred is a vector comprising a polynucleotide sequence selectedfrom SEQ ID NO: 1 to 5.

In preferred embodiments a virus-like particle of the inventioncomprises

(1) the same type of a surface protein from two or three differentstrains or serotypes of the same virus;

(2) a mixture of more than two different surface proteins from differentviral strains, e.g. from influenza virus strains H5N1 and H1N1;

(3) a mixture of different surface proteins combined from virusesspecific for different hosts, e.g. from influenza virus specific forswine, human and/or avian hosts.

Viruses considered as source for epitopes to be comprised in virus-likeparticles of the invention are, for example, influenza virus, HPV, HIV,CMV, Dengue, HCV and Newcastle Disease Virus. Epitopes may be derivedfrom other viruses and from bacteria. Particularly preferred isinfluenza virus. Equally preferred is human papilloma virus (HPV).

Vectors considered are DNA vectors, and can either be a plasmid vectoror a viral vector. Methods to assemble such vectors are standard methodsof state of the art molecular biology. Preferred methods are MultiBacsuch as described in WO 2005/085456 and in I. Berger et al., NatureBiotechnology 22, 1583, 2004, or Polybac methods such as described in WO2007/054250, combined with CAP™ technology and state of the art genesynthesis technologies. These technologies allow assembling a multi-geneco-expression DNA vector which is suitable for expression in differenthost cells. The preferred DNA vector of the invention is a baculoviralvector.

The host cell used for the expression of vectors of the invention can beany prokaryotic (e.g. E. coli) or eukaryotic expression cell line. Forexpression of a preferred baculoviral vector an insect cell line ispreferred. Examples of insect cell lines are, e.g., SF9, SF21, Hi-5,Express Sf+, and S2 Schneider cells. For expression in a eukaryoticsystem, mammalian cells are preferred, in particular human cells, e.g.HeLa, Huh7, HEK293, HepG2, BHK, CHO, MT-2, bone-marrow fibroblasts,primary neural cells, or embryonic cells. For expression in yeast S.cerevisiae, S. pombe, C. albicans, or P. pastoris cells may be used.

Cultivation and propagation of host cells according to the invention canbe done in any vessel, bioreactor or disposable unit providing theappropriate conditions for the particular host cell.

The virus-like particles of the invention can be used as vaccines.Furthermore they may be used as antigens in diagnostic tools, antigensfor antibody generation, and as virus simulators for research anddevelopment tools, e.g. viral entry studies and virus-host interactionstudies.

Vaccines according to the invention contain the recombinant virus-likeparticle in aqueous solution optionally further containingviscosity-regulating compounds, stabilizing compounds and/or adjuvantsincreasing the immunogenicity, as is known in the state of the art.

In a particular embodiment H3N2 Influenza virus-like particles areconstructed using the methods of Berger et al., Nature Biotechnology,2004, WO2005/085456 and WO 2007/054250 and CAP™ technology. At least oneM1 and M2 gene of the H1N1 Influenza strain A/Puerto Rico/834 is clonedby PCR amplification into the transfer vector pFL (WO 2007/054250,FIG. 1) together with the HA gene of influenza A/Brisbane10/2007 and theNA gene of influenza A/Brisbane10/2007. The construct is confirmed byDNA sequencing.

In another particular embodiment the same cloning techniques are used tointroduce at least one L1 gene of both serotypes HPV16 and HPV18 orfurther serotypes from the group 2, 4, 6, 11, 31, 33-35, 39, 40-45,51-53, 55-59, 62, 66, 68, 70, 73, and 77, cloned into the transfervector pFL (FIG. 1).

Experimental Part

The baculoviral vectors termed MultiBac or YFPMultiBac (WO 2005/085456),which allow propagation in E. coli cells, and CAP™ technology are usedfor generation of recombinant AcNPVs (Autographa californica nuclearpolyhedrosis virus, a baculovirus) using a conventional system(Fitzgerald et al., Nature Methods, 3, 1021, 2006). 10 ng of themulti-gene vector is transformed in DH10MultiBac and/or DH10YFPMultiBaccompetent cells. Positive clones are selected by blue/white screeningand PCR. The corresponding MultiBac bacmid DNA is isolated using theBirnboim & Doly method. Recombinant AcNPVs are generated by transfectionof 1 μg of multi-gene MultiBac bacmid in 0.9×10⁶ Sf21 (Invitrogen) cellsusing transfection reagent Fugene (Roche) according to the manufacturersprotocol. Virus amplification is done as described previously(Fitzgerald et al., Nature Methods, 3, 1021, 2006). The titer of allrecombinant AcNPVs is determined by plaque assay described in theBac-to-Bac-Manual (Invitrogen). Protein production parameters likemultiplicity of infection (MOI), cell number (TOI) and time of harvest(TOH) are analyzed with small scale expression studies.

Example 1 Generation of Expression Vector Construct

To manufacture various constructs the multiplication module M present inthe transfer vector pFL (WO 2005/085456 and CAP™ technology) is usedaccording to the described method in WO 2005/085456. DNA of epitopes areeither obtained by isolation of viral RNA from original virus followedby reverse transcription combined with PCR (for the influenza virusepitopes) or by gene synthesis (provided by the company Geneart). Thereverse transcription is performed using the RevertAid™ H Minus Firststrand cDNA Synthesis kit (Fermentas) according to the manufacturesprotocol. The cDNA (2 μL) is used as template for PCR reaction. Thefollowing conditions are used based on the manufacturer's protocol. Fora 50 μL total volume reaction 0.2 mM dNTP (NEB), 1.2% DMSO, 0.5 μMreverse and forward primer (Microsynth), 10 μl 5× Phusion GC reactionbuffer and 2U Phusion Hot Start Polymerase (Finnzyme) are used. Formultigene assembly the appropriate restriction sites (BstZ17I, SpeI,PmelI, AvrII) are introduced using PCR. The PCR fragments are cut withthe restriction enzymes followed by ligation and transformationprocesses to integrate the multiplication module into the transfervector. The ligation is done over night at 4° C. using 500 ng linearizedtransfer vector (pFL), 4 μL PCR product and 1U T4-DNA-ligase(Fermentas). To generate the plasmid 4 μL ligation solution are added to50 μl competent DH5a cells and incubated for 30 min on ice. After a heatshock at 42° C. for 30 sec and a 2 min cold shock at 4° C., 200 μl LBmedium is added and incubated for 1 h at 37° C. and 220 rpm. Afterwards80 μl of the cell suspension is plated on LB agar plates containing theappropriate antibiotics, in this case 100 μg ampicillin and 100 μggentamycin. The whole procedure is repeated until all epitopes areintroduced into the transfer vector.

Influenza epitopes are selected from the genes HA and NA, both chosenfrom a H3N2/Brisbane10/2007 strain whereas epitopes from M1 and M2 arechosen from H1N1/Puerto Rico/834 strain. The M1 epitope is controlled bythe promoter p10, all other epitopes are controlled by the polyhedrinpromoter polh. All epitopes are present on the same vector construct(FIG. 1A, SEQ ID NO:1). Influenza B/Florida/2006 isolates are chosen togenerate a construct with multiple epitopes from the genes HA, NA, M1and M2 (FIG. 1C, SEQ ID NO:3). Human papillomavirus epitopes areselected from the gene L1 from the cancer relevant serotypes HPV16 andHPV18 and are unified in one vector construct. Both epitopes arecontrolled by the polyhedrin promoter polh (FIG. 1B, SEQ ID NO:2). Toimprove the expression yield the p10 promoter is deleted in a furtherconstruct (FIG. 1E, SEC ID NO:5). In another construct HPV16 epitope iscontrolled by p10 promoter whereas the polyhedrin promoter polh ischosen for the HPV18 epitope (FIG. 1D, SEQ ID NO:4).

Example 2 Generation of Recombinant Baculovirus

This virus contains multiple epitopes to generate virus-like particlesor virus simulators which present these epitopes on their surface. Thevirus-like particles can be used for different applications, e.g. asvaccines in the influenza field. The AcNPV-derived baculovirus containsmultiple different epitopes from the viral strains recommended by WHOfor the 2008/2009-VLP vaccination campaign. All genes of the transfervector are transposed by site specific homologous recombination intoMultiBac cells according to the protocol of WO 2005/085456.

10 ng transfer vector are added to 100 μl MultiBac competent cells andincubated for 30 min at 4° C. After a heat shock at 42° C. for 45 secand a 2 min cold shock at 4° C. 400 μl LB medium is added and the cellsolution is incubated for 4 h at 37° C. and 220 rpm. Different dilutionsare plated on appropriate LB agar plates containing various antibioticresistances. Based on blue/white and PCR screening several correctMultiBac clones are selected. The corresponding MultiBac bacmid DNA isisolated using the Birnboim & Doly method. At least four MultiBac bacmidclones are selected for initial transfection of insect cells like Sf9 orSf21 to generate the recombinant AcNPV-derived baculovirus. This isgenerated by transfection of 1 μg of multi-gene MultiBac bacmid in0.9×10⁶ Sf21 (Invitrogen) cells using transfection reagent Fugene(Roche) according to the manufacturer's protocol. Virus amplification isdone as described previously (Fitzgerald et al., Nature Methods, 3,1021, 2006; Bac-to-Bac-Manual, Invitrogen). The virus is amplified toexpand the volume and increase the infectious titer which is determinedby plaque assay according to Bac-to-Bac-Manual (Invitrogen). The bestexpression construct is determined by 50 mL small scale expressionexperiments followed by determination of protein yield by Bradford Assay(ADV, Cytosceleton). Expression of best expressor is further verified byWestern blot analysis with antibodies against the multiple differentepitopes (FIG. 2A).

Example 3 Production and Purification of Multi-Epitope InfluenzaVirus-Like Particles in Insect Cells

After determination of the best expression construct thebiotechnological production parameters like cell line, cell amount(TOI), amount of recombinant virus inoculum (multiplicity of infection,MOD and time of harvest (TOH) are determined in 50 mL bioreactors. Amatrix of different TOI, MOI and TOH are designed according to EibI,Riesen and John (Bioforum 03/2009) and Friesen J. (Bachelor thesis,University of Applied Science, Esslingen, Germany). The expression ofsecreted or intracellular multi-epitope virus-like particles is observedfor six to eight days with daily sample taking. For intracellularparticles (e.g. HPV) the cell pellets are lysed with 50 mM TrisCl, pH7.6, 100 mM NaCl, 0.1% TritonX100 and centrifuged for 10 min, at 4° C.and 8000×g. The epitopes of the virus-like particles present in thesupernatant are further verified using a Dot-blot apparatus (Biometra)followed by Western blotting with specific antibodies. Conditionsresulting in the highest yield are defined as expression parameterspreferring a harvest time between three and four days. According tothese defined parameters the virus-like particles are produced either inshaker flasks or wave cultibags in fall armyworm Spodoptera frugiperdacells Sf9 and Sf21. For multi-epitope influenza virus-like particlesexpression Sf21 cells are chosen with the following conditions: 1.5×10⁶cells/mL, MOI 0.05 and harvest time at day four post infection. Cellsare propagated at 27° C. without carbon dioxide and fetal calf serumsupplementation. According to defined time of harvest the secretedvirus-like particles are collected by centrifugation at 500-1000×g for20 min at 4° C. The supernatant volume containing the particles isreduced for purification by tangential flow filtration using cassettes(Sartocon-Slice 200, Sartorius and CentramateOS, PALL) with a cut-off of100 kDa. The purification of virus-like particles is performed withscalable chromatographic methods and sucrose gradientultracentrifugation.

The chromatographic purification is a multi-step purification usingcation exchange, anion exchange and gel filtration chromatography. Thesupernatant is loaded onto a CaptoQ column connected to an FPLC-system(AEKTA purifier, GE Healthcare) in 50 mM phosphate buffer, pH 7.4. Theparticles are eluted with increasing salt concentrations in a lineargradient using 50 mM phosphate, 1 M NaCl, pH 7.4. The particlecontaining fractions are pooled and further purified by gel filtrationchromatography (VLP from SEQ ID NO:1, FIG. 3). The purification isperformed in 50 mM phosphate, 150 mM NaCl, pH 7.4 buffer using aHighLoad Superdex 200 μg column. All chromatography steps are analyzedby SDS-PAGE followed by coomassie staining and immunoblotting.

Example 4 Analysis of Purified Influenza Virus-Like Particles

To confirm the presence of the different epitopes purified material isanalyzed by SDS-PAGE followed by coomassie staining or Western blot. 150μl of different chromatography fractions are loaded on a 4-12% Bis-TrisNuPAGE gel (Invitrogen), run for 15 min at 150 V and for 45 min at 175 Vand coomassie stained using SimplyBlueSafestain (Invitrogen). Forimmunoblotting the proteins are transferred onto a nitrocellulosemembrane (BioRAD) at 19 V for 40 min using a semi-dry apparatus(BioRAD). After blocking unspecific binding sites for 30 min with 5%non-fat-dry-milk-TrisCl-Tween20 (0.1%) solution, the membrane isincubated over night at 4° C. with antibodies against HA, NA and matrixproteins. The membrane is washed several times with TrisCl-Tween20(0.1%) buffer. Dependent on the source of primary antibody the secondantibody is either an anti-mouse or anti-rabbit connected with alkalinephosphatase or horse-radish-peroxidase for detection. A co-localizationof these proteins show the assembly and the production derived from oneexpression vector and one baculovirus (FIG. 3B, from SEQ ID NO:1). Thisco-localization can also be shown for the expression constructscontaining the genes HA, NA and both matrix proteins M1 and M2 includingtheir membrane anchors.

Example 5 Functionality of Influenza Virus-Like Particles (VLP)

To analyze if the VLPs correctly integrate the hemagglutinin protein(HA) in their surface, a standard hemagglutination assay using red bloodcells (RBC) from chicken is performed (FIG. 4, VLP from SEQ ID NO:3).Twofold serial dilutions of the purified VLPs are carried out with PBS(1×) in V-formed 96 well plates. An equal amount of erythrocytes (1%solution) is added and incubated for 1 h at 4° C. The appearance of RBCaggregates on the bottom of the well indicates lack of hemagglutination.Titers are expressed as the inverse of the highest dilution of thepurified VLP solution to agglutinate RBCs. The results obtained showthat VLPs are able to agglutinate chicken erythrocytes and demonstrateindirectly the presence of HA on the VLP surface. The negative control(PBS) shows no agglutination.

Example 6 In Vivo Evaluation of Influenza VLP

The immunogenicity (stimulation of immune system) of VLPs (prepared fromSEQ ID NO:3) is tested in vivo using two groups of mice which aresubcutaneously immunized in a prime boost schedule at week 0 and week 3respectively. Immunization is performed using 50 or 100 μl (50 or 100ng) of VLPs in suspension. To determine the quality of the immuneresponse of the VLPs alone, no adjuvant is used. Mice are bled at week 3and 6 and sera are analyzed to look for antibody responses against theimmunized VLPs. Results obtained show that VLPs are effective atstimulating an antibody immune response. The best results are obtainedwhen immunization is performed with 100 μl, indicating a dose dependentimmune response. A clear increase of the amount of anti-VLP antibodiesis observed after boost. As expected, naïve animals show no immuneresponse.

To reconfirm the specificity of the immune response, a hemagglutinationinhibition test is performed at week 6 to analyze the presence ofspecific anti-HA antibodies. The results show that specificanti-Influenza-HA antibodies are able to inhibit erythrocyteagglutination up to a dilution 128 (mouse 6) and a dilution 256 (mouse8). No hemagglutination inhibition is observed with sera sample of thenaïve mouse. Newly generated multi-epitope influenza-VLPs are able tostimulate the immune system in a dose dependent manner. When the immunesystem is re-stimulated with a boost, the immune response increases atleast 15 times. The specificity of the elicited immune response isanalyzed by ELISA and a hemagglutination test.

Example 7 Production and Purification of Multi-Epitope Virus-LikeParticles Carrying Human Papillomavirus Epitopes in Various Cell Lines

The biotechnological production parameters like cell line, cell amount(TOI), amount of recombinant virus inoculum (multiplicity of infection,MOI) and time of harvest (TOH) are determined in 50 mL bioreactors (FIG.7) according to EibI et al. (Bioforum 3/2009). According to thesedefined parameters the virus-like particles are produced either inshaker flasks or wave cultibags in fall armyworm Spodoptera frugiperdacells Sf9 and Sf21. Multiple-epitope papilloma virus-like particles areexpressed from SEQ ID NO:2 in Sf21 cells using 2×10⁶ cells/mL, MOI 0.5and harvest time at day three post infection. Cells are propagated at27° C. without carbon dioxide and fetal calf serum supplementation. Atdefined harvest time (three days post infection) intracellularvirus-like particles are collected by centrifugation at 500-1000×g for20 min at 4° C. The cells are lysed using hypotonic phosphate buffersfollowed by ultrasonication. After a centrifugation step at 4° C. and2000×g the supernatant was collected. The purification of virus-likeparticles is performed with scalable chromatographic methods and sucrosegradient ultracentrifugation. The chromatographic purification is amulti-step purification using cation exchange, anion exchange and gelfiltration chromatography. The supernatant is loaded onto a CaptoDEAEcolumn connected to an FPLC-system (AEKTA purifier, GE Healthcare) in 50mM phosphate buffer, pH 7.4. The particles are eluted with increasingsalt concentrations in a linear gradient using 50 mM phosphate, 1 MNaCl, pH 7.4 (FIG. 8A). The particle containing fractions are pooled andfurther purified using a hydroxyapatite column. Binding is performed in20 mM phosphate buffer, pH 7.0 followed by linear gradient elution with500 mM phosphate, 150 mM NaCl, pH 7.0. To polish the multi-epitopeparticles a gel filtration chromatography is done. The purification isperformed in 50 mM phosphate, 150 mM NaCl, pH 7.4 buffer using aHighLoad Superdex 200 μg column. All chromatography steps are analyzedby SDS-PAGE followed by coomassie staining and immunoblotting.

Example 8 Analysis of Purified Chimeric Human Papilloma Virus-LikeParticles

To confirm the presence of the different epitopes in purified material,the VLP prepared from SEQ ID NO:2 is analyzed by SDS-PAGE followed bycoomassie staining (FIG. 8B) and Western blot (FIG. 8C). Forimmunoblotting antibodies against L1 protein of different serotypes areused. 150 μl of different chromatography fractions are loaded on a 4-12%Bis-Tris NuPAGE gel (Invitrogen), run for 15 min at 150 V and a for 45min at 175 V and coomassie stained using SimplyBlueSafestain(Invitrogen). For immunoblotting the proteins are transferred onto anitrocellulose membrane (BioRAD) at 19 V for 40 min using a semi-dryapparatus (BioRAD). After blocking unspecific binding sites for 30 minwith 5% non-fat-dry-milk-TrisCl-Tween20 (0.1%) solution, the membrane isincubated over night at 4° C. with antibodies against L1 epitopes.Camvir antibody (SantaCruz) is used for HPV16 and anti-HPV18ab (Abcam)for HPV18 detection. The membrane is washed several times withTrisCl-Tween20 (0.1%) buffer. The membrane is incubated for 1 h with ananti-mouse antibody connected with alkaline phosphatase for detection.The epitopes are detected by BCIP/NPT solution. A co-localization ofthese proteins show the assembly and production derived from oneexpression vector and one baculovirus.

Example 9 Functionality of Chimeric Human Papilloma Virus-Like Particles(VLP)

To analyze if the human papilloma virus-like particles prepared from SEQID NO:2 correctly integrate the L1 protein in their surface, a standardELISA assay is performed. Twofold serial dilutions of the purified VLPsare carried out with PBS (1×) in V-formed 96 well plates. An equalamount of a serotype specific antibody (concentration 1:1000) is addedand incubated for 1 h at 37° C. Appropriate binding of the antibody tothe L1 protein is detected using a second antibody with a horse-radishperoxidase and a chemoluminescent detection system. The results obtainedshow binding of antibodies to the recombinant expressed epitopes in adose dependent manner. The negative control (PBS) showed no binding.

1-16. (canceled)
 17. A single baculoviral vector encoding a recombinantvirus-like particle comprising (i) two or more polynucleotides codingfor different epitopes or different proteins comprising epitopes whichare selected either (a) from different viral strains of the same virusand/or (b) from different serotypes of the same virus and/or (c) fromdifferent viral strains specific for different hosts; (ii)polynucleotides coding for proteins forming a complete virus-likesurface; and (iii) polynucleotides coding for capsid and/or nucleoporeproteins.
 18. The baculoviral vector according to claim 17 comprisingthree or more different epitopes or different proteins comprisingepitopes.
 19. The baculoviral vector according to claim 17 comprisingfour or more different epitopes or different proteins comprisingepitopes.
 20. The baculoviral vector according to claim 17 comprisingsix, nine or twelve epitopes or different proteins comprising epitopes.21. The baculoviral vector according to claim 17 wherein the epitopesare from three or more different virus strains or serotypes.
 22. Thebaculoviral vector according to claim 17 further comprising B- and/orT-cell epitopes.
 23. The baculoviral vector according to claim 17further comprising fluorescent proteins, proteins useful forpurification purposes of the particles or for attaching a label, and/orproteinaceous structures required for transport processes.
 24. Thebaculoviral vector according to claim 17 wherein the virus is influenzavirus.
 25. The baculoviral vector according to claim 17 wherein thevirus is human papilloma virus.
 26. A single baculoviral vectorcomprising a polynucleotide selected from SEQ ID NO:1-5.
 27. A host cellcomprising a vector according to claim
 17. 28. A host cell comprising avector according to claim
 18. 29. A host cell comprising a vectoraccording to claim
 19. 30. A host cell comprising a vector according toclaim
 20. 31. A host cell comprising a vector according to claim
 21. 32.A host cell comprising a vector according to claim
 22. 33. A host cellcomprising a vector according to claim
 23. 34. A host cell comprising avector according to claim
 24. 35. A host cell comprising a vectoraccording to claim
 25. 36. A host cell comprising a vector according toclaim 26.